Published in ACS Nano on August 09, 2012
Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release (2013) 1.08
Theranostic nanoparticles. J Nucl Med (2014) 1.03
Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging (2015) 0.97
Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages. Mol Ther Nucleic Acids (2013) 0.94
⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem (2014) 0.94
Targeted nanotechnology for cancer imaging. Adv Drug Deliv Rev (2014) 0.91
In-fiber production of polymeric particles for biosensing and encapsulation. Proc Natl Acad Sci U S A (2013) 0.90
Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen. Angew Chem Int Ed Engl (2015) 0.87
Molecular imaging of the tumor microenvironment for precision medicine and theranostics. Adv Cancer Res (2014) 0.85
Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. J Nucl Med (2015) 0.85
Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol Pharm (2013) 0.84
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett (2012) 0.82
Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol (2015) 0.82
Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. Mol Ther (2016) 0.78
Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast. Int J Nanomedicine (2015) 0.76
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol (2016) 0.76
Degradable Dextran Nanopolymer as a Carrier for Choline Kinase (ChoK) siRNA Cancer Therapy. Nanomaterials (Basel) (2016) 0.75
Ultrahigh affinity Raman probe for targeted live cell imaging of prostate cancer. Chem Sci (2016) 0.75
Magnetic Resonance Spectroscopy of siRNA-Based Cancer Therapy. Methods Mol Biol (2016) 0.75
Therapeutic efficacy of nanomedicines for prostate cancer: An update. Investig Clin Urol (2016) 0.75
NIH workshop on clinical translation of molecular imaging probes and technology--meeting report. Mol Imaging Biol (2014) 0.75
Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting. Mol Cancer Ther (2016) 0.75
Mechanism of three-component collision to produce ultrastable pRNA three-way junction of Phi29 DNA-packaging motor by kinetic assessment. RNA (2016) 0.75
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials (2015) 0.75
(111)In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues. Biomacromolecules (2016) 0.75
Oligonucleotide-based theranostic nanoparticles in cancer therapy. Nanomedicine (Lond) (2016) 0.75
MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro. Dig Dis Sci (2017) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16
Mechanisms of gene silencing by double-stranded RNA. Nature (2004) 16.82
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Transport of molecules in the tumor interstitium: a review. Cancer Res (1987) 5.74
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst (2006) 4.01
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007) 3.64
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol (2012) 3.09
Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target (2007) 2.50
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol (2007) 1.95
siRNA-based approaches in cancer therapy. Cancer Gene Ther (2006) 1.91
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A (2012) 1.90
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71
Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjug Chem (2002) 1.55
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem (1996) 1.52
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol (2003) 1.50
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging (2003) 1.49
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med (2002) 1.36
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm (2009) 1.36
Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem (2008) 1.33
Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem (2001) 1.32
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res (2001) 1.18
Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl (2011) 1.18
Choline kinase: an important target for cancer. Curr Med Chem (2006) 1.16
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol (2004) 1.11
Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr Drug Deliv (2011) 1.08
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate (2004) 1.07
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res (2008) 1.07
Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release (2010) 1.02
Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity. Mol Pharm (2010) 1.01
Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano (2010) 1.01
Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res (2008) 1.01
Influence of nano-carrier architecture on in vitro siRNA delivery performance and in vivo biodistribution: polyplexes vs micelleplexes. ACS Nano (2011) 0.98
N-Alkyl-PEI-functionalized iron oxide nanoclusters for efficient siRNA delivery. Small (2011) 0.97
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med (2011) 0.95
In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J (2010) 0.95
Multimodal image-guided enzyme/prodrug cancer therapy. J Am Chem Soc (2006) 0.95
Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers. Biomaterials (2012) 0.92
The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents (2002) 0.91
Applications of ultrasmall superparamagnetic iron oxide contrast agents in the MR study of animal models. NMR Biomed (2004) 0.90
Novel gene-directed enzyme prodrug therapies against prostate cancer. Expert Opin Investig Drugs (2006) 0.87
Conjugation of poly-L-lysine to bacterial cytosine deaminase improves the efficacy of enzyme/prodrug cancer therapy. J Med Chem (2008) 0.81
Theranostic imaging of cancer. Eur J Radiol (2012) 0.75